Please assess the completion status of the following clinical trial:

Trial Title: Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diffuse large B-cell lymphoma (DLBCL) (de novo or DLBCL transformed from follicular lymphoma on the basis of a tissue biopsy).~* Received at least one prior therapy for aggressive Non-Hodgkin's Lymphoma (NHL) (DLBCL).~* Received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) + rituximab or equivalent regimen.~* Patients must have measurable disease.~* Not eligible or not willing to receive the high-dose (myeloablative) chemotherapy (HDC) and stem cell transplant (SCT).~* A fresh tumor biopsy collected during screening and /or archival tumor tissue collected after the last relapse/disease progression.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.~* Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal (LLN) for the Institution. (as per local standard of care) as measured by echocardiogram (ECHO) or Multiple gated acquisition (MUGA) scan.~* Adequate bone marrow, liver and renal function.~Exclusion Criteria:~* Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only.~* Active CTCAE (Common Terminology Criteria for Adverse Events) Grade 3/4 infection.~* Current central nervous system (CNS) involvement by lymphoma.~* Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction within the past 6 months before start of study treatment.~* Uncontrolled arterial hypertension despite optimal medical management (per investigator's opinion).~* Type I or II diabetes mellitus with HbA1c \> 8.5% at Screening.~* New York Heart Association (NYHA) class III or IV heart disease.~* History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator).~* Patients who previously received therapy with copanlisib or other PI3K inhibitors are not eligible for enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copanlisib (Aliqopa, BAY80-6946) (Type: EXPERIMENTAL): Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)

Based on this trial design, predict the completion outcome and termination type (if applicable).